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tudinal follow-up of children and adults with pulmonary hypertension (PH). However, the procedure is invasive and has
risks associated with both the procedure and recovery period.
OBJECTIVES The purpose of this study was to identify risk factors for catastrophic adverse outcomes in children with
PH undergoing cardiac catheterization.
METHODS We studied children and young adults up to 21 years of age with PH undergoing 1 or more cardiac cathe-
terization at centers participating in the Pediatric Health Information Systems database between 2007 and 2012. Using
mixed-effects multivariable regression, we assessed the association between pre-speciﬁed subject- and procedure-level
covariates and the risk of the composite outcome of death or initiation of mechanical circulatory support within 1 day of
cardiac catheterization after adjustment for patient- and procedure-level factors.
RESULTS A total of 6,339 procedures performed on 4,401 patients with a diagnosis of PH from 38 of 43 centers
contributing data to the Pediatric Health Information Systems database were included. The observed risk of composite
outcome was 3.5%. In multivariate modeling, the adjusted risk of the composite outcome was 3.3%. Younger age at
catheterization, cardiac operation in the same admission as the catheterization, pre-procedural systemic vasodilator
infusion, and hemodialysis were independently associated with an increased risk of adverse outcomes. Pre-procedural use
of pulmonary vasodilators was associated with reduced risk of composite outcome.
CONCLUSIONS The risk of cardiac catheterization in children and young adults with PH is high relative to previously
reported risk in other pediatric populations. The risk is inﬂuenced by patient-level factors. Further research is necessary
to determine whether knowledge of these factors can be translated into practices that improve outcomes for children
with PH. (J Am Coll Cardiol 2015;66:1261–9) © 2015 by the American College of Cardiology Foundation.m the *Division of Cardiology, The Children’s Hospital of Philadelphia, and Department of Pediatrics, Perelman School of
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ICD-9 = International
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Revision
IPAH = idiopathic pulmonary
arterial hypertension
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PH = pulmonary hypertension
PHIS = Pediatric Health
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1262P ulmonary hypertension (PH) affects2.1 to 3.7 children per million (1–3)but remains an extremely morbid
condition, with a 5-year survival of 65% to
75% (1,2,4–6). Right-sided heart catheteriza-
tion is an important tool in the diagnosis,
classiﬁcation, and longitudinal care of these
patients (7,8); however, cardiac catheteriza-
tion in children with PH carries a risk of car-
diac arrest of 4.5 to 5.7 per hundred (9,10),
which is >10 times the risk of catheterization
in children with other diagnoses and in
adults with PH (11–20).SEE PAGE 1270The determinants of periprocedural
morbidity and mortality are not well deﬁned,
particularly in children. Relatively small
procedural volumes at single centers and
differences in practice at different centers
are obstacles to the study of outcome in
children with PH. Identiﬁcation of risk fac-tors for adverse outcomes could provide an oppor-
tunity to intervene and improve the safety of
catheterization in children with PH.
We performed a multicenter retrospective cohort
study assessing risk factors for catastrophic adverse
events using the Pediatric Health Information Sys-
tems (PHIS) database, an administrative database. We
hypothesized that patient-level risk factors, such as
age, pathogenesis of PH, and indicators of severity of
illness, would inﬂuence the periprocedural risk of
death and catastrophic outcome.
METHODS
DATA SOURCE. The PHIS is an administrative data-
base that contains data from inpatient, emergency
department, ambulatory surgery, and observation
encounters from 43 nonproﬁt tertiary care pediatric
hospitals afﬁliated with the Children’s Hospital
Association (Overland Park, Kansas) in the United
States. Encounters in PHIS include inpatient and
observation admissions but exclude outpatient pro-
cedures (those without overnight observation). Data
quality and reliability are ensured through a joint
effort between the Children’s Hospital Association
and participating hospitals. The data warehouse
function for the PHIS database is managed by Truventhors have reported that they have no relationships relevant to t
co-senior authors of this work.
is manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
received March 9, 2015; revised manuscript received June 12, 20Health Analytics (Ann Arbor, Michigan). For the
purposes of external benchmarking, participating
hospitals provide discharge/encounter data including
demographics, diagnoses, and procedures. Forty-two
of these hospitals also submit resource utilization
data (e.g., pharmacy products, radiologic studies, and
laboratory studies) to the PHIS. Data are deidentiﬁed
at the time of data submission and are subjected to a
number of reliability and validity checks before being
included in the database. A data-use agreement
was signed between study investigators and the
Children’s Hospital Association. The institutional re-
view board of The Children’s Hospital of Philadelphia
reviewed the proposed project and determined that it
did not represent human subjects research in accor-
dance with the Common Rule [45 CFR 46.102(f)].
STUDY POPULATION. Procedures and diagnoses
were identiﬁed by International Classiﬁcation of
Disease-9th Revision (ICD-9) codes. We included
children and adults, age 0 to 21 years, who had a
diagnosis of PH and were undergoing cardiac cathe-
terization at any of the 43 PHIS centers between
January 1, 2007, and December 31, 2012. We excluded
subjects from centers reporting <25 cardiac cathe-
terization procedures per year or not reporting car-
diac catheterization procedures in at least 4 of 6 years
during the study period to ensure that only centers
with stable reporting practices were included. Sub-
jects for whom the date of catheterization was
missing were also excluded. Subjects undergoing
electrophysiology studies and those undergoing car-
diac catheterization on mechanical circulatory sup-
port were excluded because their risk of adverse
event was considered to be qualitatively different.
STUDY MEASURES. Data were extracted from the
PHIS database by direct query with use of ICD-9 codes
and clinical transaction codes for pharmaceutical
products as described previously (Online Table 1).
The primary outcome was a composite of death or
initiation of mechanical circulatory support (extra-
corporeal membrane oxygenation [ECMO], percuta-
neous ventricular assist device, or balloon pump)
within 1 day of cardiac catheterization. Patient-level
data included subject age, sex, race, insurance payer
(private, public, other), presence of genetic syndrome
(21), presence of noncardiac congenital anomalies,
history of prematurity (deﬁned as gestational age <34he contents of this paper to disclose. Drs. Rome and
ntin Fuster.
15, accepted July 6, 2015.
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1263weeks in patients <1 year of age), location of patient
before the procedure (outpatient, neonatal intensive
care unit, intensive care unit, cardiac intensive care
unit, and step-down unit/cardiac unit), receipt of
mechanical ventilation before catheterization, and
receipt of inotropic agents, systemic vasodilators, and
pulmonary vasodilators. Subclassiﬁcation of PH was
limited in this database to: 1) idiopathic pulmonary
arterial hypertension (IPAH); 2) pulmonary arterial
hypertension associated with congenital heart dis-
ease (APAH-CHD); 3) PH with cardiomyopathy, 4) PH
in the context of a heart transplant, and 5) chronic
thromboembolic pulmonary hypertension (CTEPH).
Diagnoses were based on ICD-9 codes extracted by
coders based on physician documentation and sent to
the Children’s Hospital Association. Further details
regarding diagnoses and clinically relevant data such
as oximetry, pressure data, laboratory data, and im-
aging data were not available. Procedural data
included whether a transcatheter intervention was
performed during the case.
For some covariates identiﬁed before analysis
(such as race and cardiac diagnosis), data were
missing in <10% of cases. For these subjects, data
were coded as “missing” and included in the analysis.
There were no other missing data.
STATISTICAL ANALYSIS. Descriptive statistics were
expressed as mean  SD, median (range and inter-
quartile range [IQR]), and percentages and counts as
appropriate. Multiple catheterizations were per-
formed on individual subjects over the study period.
All eligible procedures were included, and all statis-
tics are reported per procedure except where noted.
The association between patient-level characteris-
tics and composite outcome was assessed with
mixed-effects multivariate generalized linear models
(with logistic link) (22). Fixed effects for the pre-
speciﬁed covariates (listed above) were included. To
account for covariance within centers and between
multiple procedures performed in a single patient,
random intercepts were added to the model for each
center and patient (23). An additional analysis
restricted to the ﬁrst catheterization for each subject
during the study period was performed as an alter-
native means of accounting for bias introduced by the
inclusion of multiple catheterizations per subject.
Adjusted risks of outcomes were estimated with
conditional standardization (i.e., the risk estimated
by the model if variables were set at either the mean
values for the cohort for continuous variables or at
the referent group for categorical variables) to pro-
vide a more clinically applicable estimation of risk.
On the basis of previous research (24), an interactionterm for age category and history of prematurity was
included.
Several pre-speciﬁed sensitivity and subset analyses
were performed. A model that included PH medica-
tions by drug class (calcium-channel blockers [CCBs],
phosphodiesterase [PDE]-5 inhibitors, endothelin re-
ceptor antagonists [ERAs], and prostacyclin analogues)
was performed. We also adjusted for the number of
classes of PH medications to assess whether this pro-
vided pre-procedural risk stratiﬁcation.
Post-hoc analyses included: 1) characteristics and
outcomes of subjects in whom a catheter-based
intervention was performed versus those without
an intervention; 2) outcomes stratiﬁed by quintiles
of center annual catheterization volume (quintiles
determined as described previously [24]); and 3)
outcomes excluding subjects who underwent a car-
diac operation within 1 day of catheterization. The
latter analysis was performed to assess the effect of
pre-operative catheterizations at centers that used
routine post-operative ECMO in high-risk patients on
observed results. This may also have eliminated
subjects who experienced clinical decompensation
and subsequent ECMO.
All analyses were performed with Stata MP version
13 (StataCorp, College Station, Texas). The threshold
for statistical signiﬁcance was set at p < 0.05.
RESULTS
STUDY POPULATION. The initial query yielded data
from 7,049 procedures performed in 4,818 subjects
during 6,180 hospitalizations at 43 centers (Figure 1).
Twenty-two procedures (0.3%) on 18 subjects from
5 centers were excluded because the centers re-
ported fewer than 25 catheterizations per year or did
not report any catheterization procedures in at least
4 of the 6 years of the study period. Twenty-ﬁve
procedures (0.4%) in 14 subjects were excluded
because of missing date of catheterization, and 663
procedures (9%) on 385 subjects were excluded
because of mechanical circulatory support before
and on the day of catheterization. Thus, the study
sample included 6,339 procedures in 4,401 unique
subjects from 5,651 hospitalizations across 38
centers.
The median age at catheterization was 2.2 years
(range 2 days to 21 years) (Table 1). Fifty-one percent
of catheterizations were performed in subjects who
were male, 62% in whites, and 38% in those with
private insurance. Twenty-one percent of procedures
were performed in subjects with IPAH, 69% with
APAH-CHD, 6% with PH and cardiomyopathy, 4%
with PH after an orthotopic heart transplant, and
FIGURE 1 Study Population
7,049 procedures
4,818 unique subjects
43 centers
Center excluded
5 centers
22 procedures
18 subjects
7,027 procedures
4,800 unique subjects
38 centers
Missing date of catheterization
25 procedures
14 subjects
7,002 procedures
4,786 unique subjects
38 centers
ECMO prior to date of
catheterization
663 procedures
385 subjects
6,339 procedures
4,401 unique subjects
38 centers
Flow chart detailing progress from initial data query to the analytic cohort based on
exclusion criteria for centers, missing date of catheterization, and receipt of extracorporeal
membrane oxygenation (ECMO) before catheterization.
TABLE 1 Study Population
Catheterization procedures 6,339
Individual patients 4,401
Age, yrs 2.2 (210 days to
9.5 yrs; 2 days
to 21 yrs)
Age categories
Neonate with prematurity 0.3 (21)
Neonate without prematurity 3.3 (207)
Infant (30 days to 1 yr) with prematurity 3.7 (236)
Infant (30 days to 1 yr) without prematurity 28 (1,827)
1–8 yrs 36 (2,279)
8–18 yrs 24 (1,503)
>18 yrs 4.2 (266)
Male 51 (3,236)
Race
White 62 (3,920)
Black 14 (917)
Asian 3 (216)
Other 16 (998)
Missing 5 (288)
Payer
Private 38 (2,430)
Medicaid 43 (2,716)
Other 19 (1,193)
Diagnosis
IPAH 21 (1,304)
APAH-CHD 69 (4,357)
Cardiomyopathy with PH 6 (359)
Chronic thromboembolic pulmonary
hypertension
1 (49)
PH with orthotopic heart transplant 4 (270)
Genetic syndrome 18 (1,126)
Noncardiac congenital anomaly 12 (752)
Mechanical ventilation before catheterization 16 (1,038)
Medications before catheterization
PDE-5 inhibitors 10 (624)
Calcium-channel blockers 5 (335)
Prostacyclin analogues 1.1 (77)
ERAs 6 (349)
Inhaled nitric oxide 0.1 (5)
Inotropic agents 13 (817)
Systemic vasodilators 10 (641)
Hemodialysis 0.2 (15)
Cardiothoracic operation before catheterization
during the same hospitalization
5 (324)
Transcatheter intervention during catheterization 23 (1,441)
Outcomes
Composite outcome within 1 day 3.5 (222)
Death within 1 day 0.3 (17)
ECMO within 1 day 3.3 (206)
Composite outcome on day of catheterization 1.0 (61)
Death on day of catheterization 0.1 (9)
ECMO on day of catheterization 0.8 (52)
Values are n, median (interquartile range; range), or % (n).
APAH-CHD ¼ pulmonary arterial hypertension associated with congenital heart
disease; ECMO ¼ extracorporeal membrane oxygenation; ERA ¼ endothelin
receptor antagonist; IPAH ¼ idiopathic pulmonary arterial hypertension; IQR ¼
interquartile range; PAH ¼ pulmonary arterial hypertension; PDE ¼
phosphodiesterase; PH ¼ pulmonary hypertension.
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12641% with CTEPH. Before catheterization, 5% were
receiving CCBs, 10% were receiving PDE-5 inhibitors,
6% were receiving ERAs, 1.1% were receiving contin-
uous intravenous prostacyclin analogues, and 0.1%
were receiving inhaled nitric oxide. Overall, 13% were
receiving inotropes and 9% systemic vasodilators.
During the same hospitalization and before cathe-
terization, 5% of subjects had undergone a cardiac
operation. During the catheterization, 23% of subjects
underwent a transcatheter intervention.
Catheterizations that included a transcatheter
intervention were performed in subjects who were
younger (p < 0.001), more likely male, and of “other”
race. Such procedures also had a higher proportion of
APAH-CHD (89% vs. 62.8%) and a lower proportion of
IPAH (6.9% vs. 24.6%; p < 0.001), a lower proportion
receiving pulmonary vasodilators (14.9% vs. 19.0%;
p < 0.001), a higher proportion receiving systemic
vasodilators (12.7% vs. 9.4%; p < 0.001), and a higher
proportion who had undergone a cardiac operation
during the same hospitalization (8.7% vs. 4.1%;
TABLE 2 Multivariate Model of Risk Factors for Combined Outcome
(Random Intercept, With Interaction Between Age Category and Prematurity)
Odds Ratio 95% CI p Value
Age
0 to 30 days with prematurity 4.95 1.30–18.86 0.02
0–30 days without prematurity 1.63 0.84–3.17 0.15
30 days to 1 yr with prematurity 0.99 0.45–2.20 0.99
30 days to 1 yr without prematurity 1.61 1.14–2.28 0.007
1–8 yrs 1 N/A N/A
8–18 yrs 0.45 0.27–0.75 0.002
>18 yrs 0.48 0.17–1.38 0.17
Race
White 1 N/A N/A
Black or African-American 0.71 0.44–1.17 0.18
Asian 0.75 0.32–1.76 0.51
Other 0.86 0.56–1.31 0.48
Missing 1.63 0.95–2.79 0.08
Payer
Private insurance 1 N/A N/A
Public insurance 0.63 0.45–0.88 0.006
Other 0.81 0.53–1.24 0.32
Diagnosis
IPAH 1 N/A N/A
APAH-CHD 1.32 0.82–2.12 0.25
PAH with cardiomyopathy 1.52 0.75–3.12 0.25
PAH with orthotopic heart transplant 2.62 1.28–5.35 0.008
Chronic thromboembolic pulmonary hypertension 0.95 0.12–7.34 0.96
Genetic syndrome 0.93 0.65–1.33 0.69
Noncardiac structural anomaly 1.06 0.71–2.91 0.77
Cardiac operation before catheterization 2.57 1.28–5.35 <0.001
Pre-procedural medical care
Mechanical ventilation 0.79 0.54–1.17 0.24
Hemodialysis 19.40 5.50–68.40 <0.001
Inotropic agents 1.06 0.71–1.58 0.82
Systemic vasodilators 1.85 1.18–2.91 0.007
Pulmonary vasodilators 0.38 0.22–0.64 <0.001
Intervention during procedure 0.69 0.48–0.99 0.04
Adjusted risk of composite outcome is 3.3% (95% CI: 1.9% to 5.5%). Akaike information criteria: 1802.
CI ¼ conﬁdence interval; N/A ¼ not applicable; other abbreviations as in Table 1.
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1265p < 0.001) compared with catheterizations without an
intervention (Online Table 2). The risks of composite
outcome, death, and initiation of ECMO were not
signiﬁcantly different on the day of catheterization or
within 1 day of catheterization.
The risk of the composite outcome within 1 day
of catheterization was 3.5% (n ¼ 222) (Table 1). A
total of 206 subjects (3.3%) underwent initiation of
mechanical circulatory support, and 17 died (0.3%).
The risk of the composite outcome was 1.0% (n ¼ 61)
on the day of cardiac catheterization; 52 (0.8%)
underwent initiation of mechanical circulatory
support, and 9 died (0.1%). The risk of death before
discharge was 6.6% (n ¼ 416), with an increased risk
of death if the patient was placed on mechanical
support within 1 day of catheterization (15.1%;
p < 0.001). In the subgroup of procedures in sub-
jects with IPAH, 1.8% (25 of 1,416) underwent
ECMO, and 36% of these (9 of 16) died before
discharge.
MULTIVARIATE MODEL FOR RISK FACTORS ASSOCIATED
WITH DEATH OR MECHANICAL CIRCULATORY SUPPORT
WITHIN 1 DAY OF CARDIAC CATHETERIZATION. Table 2
and Central Illustration show the results of a mixed-
effects multivariate regression model of the risk fac-
tors for death or mechanical circulatory support
within 1 day after catheterization. Using conditional
standardization, the adjusted risk of composite pri-
mary outcome within 1 day of catheterization was
3.3% (95% conﬁdence interval [CI]: 1.9% to 5.5%).
Several factors were independently associated with
an increased risk. Neonates with history of prematu-
rity (odds ratio [OR]: 4.95; p ¼ 0.02) and infants
without prematurity (OR: 1.61; p ¼ 0.007) were asso-
ciated with an increased risk of the composite
outcome relative to subjects between >1 and #8 years
of age. Similarly, older children (age >8 and #18
years) had a reduced risk of the composite outcome
(OR: 0.45; p ¼ 0.02). Age >18 years was not associated
with a signiﬁcant change in the risk of adverse events.
In terms of diagnosis, there were no signiﬁcant dif-
ferences in risk of composite outcome for subjects
with APAH-CHD, cardiomyopathy, or CTEPH com-
pared with IPAH. However, PH after heart trans-
plantation was associated with a signiﬁcantly
increased risk (OR: 2.78; p ¼ 0.005).
Several aspects of pre-procedural medical care
were independently associated with the risk of cata-
strophic adverse outcome. Hemodialysis was associ-
ated with increased risk (OR: 19.40; p < 0.001), as was
receipt of systemic vasodilators (OR: 1.85; p ¼ 0.007).
Receipt of any PH medications was associated
with reduced risk of adverse outcome (OR: 0.38;p < 0.001). Mechanical ventilation and receipt of
inotropes were not associated with the risk of com-
posite outcome.
We also assessed the associated risk of catastrophic
adverse outcome with treatment with PH medications
by class (Online Table 3). The point estimates for
CCBs, PDE-5 inhibitors, and ERAs were similar to that
of PH medications overall (but with decreased
precision). The association between PDE-5 inhibitors
and reduced risk remained signiﬁcant (OR: 0.44;
p ¼ 0.02), whereas the observed reductions in risk
with CCBs (OR: 0.47; p ¼ 0.08) and ERAs (OR: 0.63;
p ¼ 0.34) were not statistically signiﬁcant. The num-
ber of PH medications received did not appear to
affect the results (Online Table 4).
CENTRAL ILLUSTRATION Catheterization in Children With Pulmonary Hypertension: Forest Plot of Multivariable Analysis of
Risk Factors for Catastrophic Adverse Outcome
0.04            0.2                1                  5                 25               12 0.04            0.2                1                  5                 25               12
Odds Ratio Odds Ratio
0 to 30 days with prematurity
0 to 30 days without prematurity
30 days to 1 year with prematurity
30 days to 1 year without prematurity
1 to 8 years
8 to 18 years
>18 years
Age
Payor
Pre-procedure Medical Care
Genetic Syndrome
Prior Cardiac Operation (Same Admission)
Diagnosis
Intervention During Procedure
Race
White
Black 
Asian
Other
Missing
Non-cardiac Structural Anomaly
Mechanical ventilation
Hemodialysis
Inotropic agents
Systemic vasodilators
Pulmonary vasodilators
Private insurance
Public insurance
Other
IPAH
APAH-CHD
PAH with cardiomyopathy
PAH with orthotopic heart transplant
Chronic thromboembolic disease
O’Byrne, M.L. et al. J Am Coll Cardiol. 2015; 66(11):1261–9.
These results assess process within 1 day from catheterization and depict odds ratios (blue diamonds) along with 95% conﬁdence intervals (brackets) from mixed-
effects multivariate generalized linear models. APAH-CHD ¼ pulmonary arterial hypertension associated with congenital heart disease; IPAH ¼ idiopathic pulmonary
arterial hypertension; PAH ¼ pulmonary arterial hypertension.
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1266Several post-hoc analyses were performed. The
exclusion of patients who underwent transcatheter
interventions did not change the standardized risk of
composite outcome or the previously observed asso-
ciations with other covariates (data not shown). An
analysis restricted to the ﬁrst catheterization for each
subject during the study period demonstrated no
signiﬁcant changes in the adjusted risk or the ORs for
selected covariates, which suggests that the initial
method for accounting for multiple catheterizations
per subject was effective (Online Table 5). A sensi-
tivity analysis was performed that restricted analysis
to procedures in subjects who had not undergone an
operation within 1 day of catheterization (n ¼ 6,207
of 6,339 cases). The intention of this analysis
was to eliminate subjects who had undergone a
pre-operative catheterization who then underwent
subsequent post-operative ECMO support. The stan-
dardized risk of composite outcome was 2.6%
(95% CI: 1.5% to 4.7%), with similar predictors as seen
in the main analysis (Online Table 6).
The association between catheterization laboratory
volume and adverse outcomes was measured.
The risk of composite outcome was highest in the
lowest-volume quintile (6.1%) and lowest in the
highest-volume quintile (2.4%), with a statistically
signiﬁcant association across quintiles (p < 0.001)
(Online Table 7). After adjustment for other cova-
riates, adjusted risk of death was signiﬁcantly higherat low-volume centers (quintiles 1 and 2) than at
higher-volume centers. There was no signiﬁcant dif-
ference between outcomes at centers with higher
volume (quintiles 3, 4, and 5), although a nonsigniﬁ-
cant trend toward reduced risk with higher volume
was observed (Online Tables 7 and 8).
DISCUSSION
Despite advances in noninvasive imaging technology,
cardiac catheterization remains the gold standard for
initial diagnosis, choice of initial pharmacotherapy,
and longitudinal assessment of patients with PH (7,8).
The risk of mortality with catheterization in children
(across all diagnoses) has been measured in several
single-center series, with estimates between 0.3% and
0.8% (12–15,19,24,25). Catheterization in adults with PH
has been associated with a risk of mortality of 0.05%
(26). The risk of cardiac arrest during cardiac catheter-
ization in children with PH in single-center series is
>10-fold higher than in other children undergoing
cardiac catheterization (9,10,27). The single multi-
center registry study that measured the risk of adverse
events in cardiac catheterizations in children with PH
reported no deaths in >177 cases, but the relatively
small study population introduces uncertainty, with a
1-sided 97.5%CI for themortality risk of 0% to 2.1% (28).
These studies emphasize the challenge of
measuring the risk of mortality in PH. Because PH is a
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1267rare condition, even large-volume primary children’s
hospitals perform relatively few cardiac catheteriza-
tion procedures in children and young adults with
PH. In addition, the wide spectrum of disease severity
makes appropriate adjustment for pre-procedural risk
necessary, which is challenging in small study sam-
ples. Several registries have collected data on patients
with PH (4,6). A single study from the TOPP (Tracking
Outcomes in Pediatric Pulmonary Hypertension)
registry demonstrated a risk of death after catheteri-
zation of 0.6% (95% CI: 0.2% to 1.3%) (29) but was
not sufﬁciently powered to deﬁne risk factors for
catastrophic adverse outcome. Also, TOPP is a
voluntary registry that requires informed consent for
inclusion, which potentially excluded the most
severely affected patients. In the current study, we
used administrative data to perform a retrospective
cohort study, which, with some limitations, allowed
us to measure risk of cardiac catheterization without
this bias from a broad range of pediatric hospitals and
to adjust for patient characteristics. Our population
may differ in ways from those in other series, espe-
cially those focused on IPAH, but may be more
representative of the burden of disease that is seen
at the tertiary care centers that submit data to PHIS.
The adjusted risk of death or initiation of mechanical
circulatory support within 1 day of cardiac catheteri-
zation was 2.6% to 3.3%, signiﬁcantly higher than the
previously reported risk of similar outcomes with
cardiac catheterization in children (24) and that re-
ported in adults with PH (11–20). The discrepancy
between the high risk of catastrophic adverse
outcome and the relative technical simplicity of these
procedures (unlike right-sided heart catheterization
and endomyocardial biopsy in children after ortho-
topic heart transplantation, which has a very low risk
of adverse outcome [18,24,30]) highlighted that
patient-associated factors are more inﬂuential than
procedural characteristics in determining overall risk
in this case.
This study identiﬁed patient-speciﬁc factors that
may be useful in stratifying patients according to
risk. As noted in previous studies (17,31–33), infants
and especially premature infants with PH had a
higher risk than other children with PH, with gener-
ally lower risks with increasing age. Exceptions to
this pattern were neonates without prematurity, in-
fants with history of prematurity, and subjects
>18 years of age, in whom risk was not signiﬁ-
cantly different from school-aged children. These
subpopulations were relatively small (<5% of the to-
tal study population), and the failure to demonstrate
differences may have been caused by insufﬁcient
statistical power.In addition, several markers of increased severity
of illness before catheterization were independently
associated with adverse outcome, including hemodi-
alysis, receipt of systemic vasodilators, and previous
cardiac operation during the same admission. These
presumably are markers of hemodynamic instability
and general frailty.
Transcatheter intervention was associated with a
lower risk of adverse outcome. This is counterintui-
tive, because conventional wisdom suggests that risk
should be tied to intervention. However, we found a
similar decrease in risk in a broader cohort of children
undergoing catheterization (24). Interventions may
have been more likely in patients who were relatively
well (with less chance of attempting an intervention
in patients with more severe illness). Performance of
an intervention may have indicated a reversible
anatomic issue, with the performance of an inter-
vention improving patient outcome.
The association of chronic medications with
decreased risk of adverse events should be inter-
preted with care. Diagnostic and treatment algorithms
recommend that patients undergo catheterization
before initiation of these therapies, so patients
receiving these treatments before catheterization
have necessarily survived at least 1 catheterization
and have likely demonstrated some responsiveness to
pulmonary vasodilators, which leads to selection bias.
Patients receiving PH medications and undergoing
subsequent catheterization may also have a different
risk proﬁle. Further measures to account for con-
founding by indication are necessary to clarify the
relationship between pulmonary vasodilators and risk
of catastrophic adverse outcome.
A secondary analysis identiﬁed an association be-
tween center volume and the risk of early cata-
strophic adverse outcome. The protective effect of
center catheterization volume for catheterization has
been demonstrated previously across the range of
procedures and diagnoses (24). Additional research is
necessary to identify whether this protective effect is
attributable to dispersible best practices or economy
of scale.
STUDY LIMITATIONS. Identiﬁcation of subjects relied
on ICD-9 codes from administrative data. As evi-
denced by a large number of subjects not receiving
medications and a large number of APAH-CHD pa-
tients, the population described in this study may
differ from those cited in other studies (especially
those focused on IPAH). The detail available, espe-
cially in regard to the speciﬁc anatomy of patients
with APAH-CHD, was limited. Post-hoc analyses were
performed to determine the degree to which APAH-
CHD patients inﬂuenced the risk of catastrophic
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Car-
diac catheterization in children and young adults with
pulmonary hypertension is associated with higher
risks of death or circulatory collapse than when per-
formed for other diagnoses. Adverse outcomes are
more frequent in younger patients and less common
in those receiving pulmonary vasodilator medications.
COMPETENCY IN INTERPERSONAL AND
COMMUNICATION SKILLS: When discussing car-
diac catheterization procedures for children with pul-
monary hypertension, physicians should explain the
risk of catastrophic outcomes to patients (when
appropriate) and their families in the context of
balancing risks against potential beneﬁts.
TRANSLATIONAL OUTLOOK: This multicenter
cohort study may lead to a better understanding of
the factors that are associated with risk of adverse
events with catheterization in children with pulmo-
nary hypertension.
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1268outcome. The PHIS database is limited to catheteri-
zations that are part of an observation or inpatient
admission, though it notably includes procedures
with subsequent hospital admission or death in the
catheterization laboratory. This may have resulted in
an overestimation of risk. Although most procedures
for PH are performed with post-procedural inpatient
observation, there are centers that do not admit
patients for observation after catheterization, espe-
cially those with mild disease. Hemodynamic and
oximetric data from the procedure, as well as addi-
tional procedural data (e.g., method of anesthesia)
and additional clinical data (e.g., imaging studies), all
of which might affect risk, were not available. The
database has a temporal resolution of a single day of
service. Choosing death or ECMO initiation on the day
of catheterization and the following date of service as
the primary outcome allowed us to capture all events
that occurred from the catheterization and the
ensuing 24 h (while including events that might have
occurred as much as 48 h later). Finally, it was not
possible to determine the degree to which observed
adverse events were the direct result of the cathe-
terization (as opposed to the result of progressive
disease or other events). In a previous study, death
before discharge was attributable to catheterization
in 10% of cases (33). Thus, the risks calculated are
necessarily inﬂated, but we hoped to mitigate this by
limiting the time horizon as described previously
(24).
CONCLUSIONS
The risk of catastrophic adverse outcome after cardiac
catheterization in children with PH was signiﬁcantly
higher than that in children with other diagnoses.
Younger age, use of pre-procedural systemic vasodi-
lators, and cardiac operation within the same admis-
sion all increased the risk of an adverse event,
whereas treatment with PH medications was associ-
ated with reduced risk. Further study is necessary to
determine how these factors interrelate and whether
a predictive model based on them would improve
outcomes of children and young adults undergoingcardiac catheterization for PH. Although administra-
tive databases have limitations, this study provides
information that may inform the design and inter-
pretation of future studies, whether they use multi-
center registry data or datasets that combine clinical
and administrative data.
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